GlassScriptPhysician profile
Gayatri Narayan
NPI 1942871207
$1,443.62
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $183 · 2022: $510 · 2023: $522 · 2024: $230.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $751.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $751.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $215.27 | 2022-2023 | Ultomiris |
| Bayer Healthcare Pharmaceuticals INC. | $180.14 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $164.61 | 2021-2024 | Opdivo, Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $157.25 | 2021-2022 | |
| Gilead Sciences, INC. | $154.27 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $138.40 | 2022-2024 | Farxiga, Breztri |
| Pfizer INC. | $86.48 | 2023-2024 | |
| Abbvie INC. | $67.87 | 2023 | |
| Novo Nordisk INC | $62.69 | 2024 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $42.86 | 2022-2023 | Trelegy Ellipta |
| Takeda Pharmaceuticals U.S.A., INC. | $37.94 | 2022-2023 | Entyvio |
| Karyopharm Therapeutics INC. | $33.29 | 2022-2024 | Xpovio |
| Argenx US, INC. | $30.55 | 2024 | Vyvgart Hytrulo |
| Seagen INC. | $24.99 | 2023 | Padcev |
| Eisai INC. | $24.99 | 2024 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $22.02 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gayatri Narayan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.